Belite Bio Inc (BLTE)
57.69
0.87 (1.53%)
At close: Feb 20, 2025, 3:57 PM
57.25
-0.76%
After-hours: Feb 20, 2025, 04:00 PM EST
undefined% (undefined)
| Bid | 56.8 |
| Market Cap | 1.78B |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -1.1 |
| PE Ratio (ttm) | -52.45 |
| Forward PE | n/a |
| Analyst | Strong Buy |
| Ask | 59.12 |
| Volume | 34,830 |
| Avg. Volume (20D) | 46,245 |
| Open | 56.99 |
| Previous Close | 56.82 |
| Day's Range | 56.74 - 58.54 |
| 52-Week Range | 31.00 - 86.53 |
| Beta | undefined |
About BLTE
Belite Bio, Inc, a clinical-stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting atrophic age-related macular degeneration and autosomal recessive stargardt diseases. Its lead product candidate is LBS-008, an oral once-a-day treatment that can reduce and maintain the delivery of vitamin A to the eye to reduce the accumulation of toxic vitamin A by-products in ocular tissue that ...
Industry Biotechnology
Sector Healthcare
IPO Date Apr 29, 2022
Employees 20
Stock Exchange NASDAQ
Ticker Symbol BLTE
Website https://belitebio.com
Analyst Forecast
According to 4 analyst ratings, the average rating for BLTE stock is "Strong Buy." The 12-month stock price forecast is $100, which is an increase of 73.34% from the latest price.
Buy 100.00%
Hold 0.00%
Sell 0.00%
1 month ago
+3.58%
Belite Bio shares are trading higher after Benchma...
Unlock content with
Pro Subscription
2 months ago
+5.34%
Belite Bio shares are trading higher after the company announced LBS-007 was granted FDA fast-track designation status for acute leukemia.
